Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis

Area of Science:

• Cardiology
• Hematology
• Genetics

Background:

• Light chain (AL) and transthyretin (ATTR) amyloidosis impact myocardial function similarly but have distinct prognoses.
• Limited data exist on subtype-specific outcome predictors in large patient cohorts.

Purpose of the Study:

• To evaluate subtype-specific predictors of outcomes in a large cohort of cardiac amyloidosis patients.
• To compare clinical, laboratory, electrical, and morphological differences between AL and ATTR amyloidosis.

Main Methods:

• Retrospective analysis of 360 cardiac amyloidosis patients (191 AL, 169 ATTR) diagnosed between 2002 and 2014.
• Multivariable Cox model analysis, stratified by amyloid-specific treatment, to identify mortality predictors.
• Evaluation of clinical, laboratory, electrical, and morphological covariates based on amyloid subtype.

Main Results:

• AL etiology was the strongest predictor of 3-year all-cause mortality (HR 3.143, P<0.001).
• ATTR patients were older with more comorbidities and used standard heart failure therapy.
• Left ventricular mass index and ECG voltage were higher in ATTR; ejection fraction and diastolic markers did not differ.
• Amyloid-specific treatment significantly impacted mortality only in AL amyloidosis (P=0.015).

Conclusions:

• Clinical, morphological, electrical, and biomarker data do not significantly interact with amyloid subtype regarding mortality.
• Prognosis differs significantly between AL and ATTR amyloidosis, suggesting factors like light chain toxicity contribute to poorer AL outcomes.